Medical Aspects of Obesity

Acta Chirurgica Belgica

Volumn , Issue 3, 1999, Pages 135-139

  Scheen, A J ^a   Luyckx, F H ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anorectic drugs; Diet; Genetics; Leptin; Obesity complications; Syndrome X

Indexed keywords

DRUG;

DIET; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROGNOSIS; REVIEW; RISK ASSESSMENT;

COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; OBESITY; PHARMACEUTICAL PREPARATIONS; PROGNOSIS; RISK ASSESSMENT;

EID: 0033124096     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. ROSENBAUM M., LEIBEL R. L., HIRSCH J. Obesity. N Engl J Med, 1997, 337 : 396-405.
2. HUBERT H. B., FEINLEIB M., MCNAMARA P. M., CASTELLI W. P. Obesity as an independent risk factor for cardiovascular disease : A 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983, 67 : 968-77.
3. JUNG R. T. Obesity as a disease. Br Med Bull, 1997, 53 : 307-21.
4. PI-SUNYER F. X. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther, 1996, 18 : 1006-35.
5. GARROW J. S. Treatment of obesity. Lancet, 1992, 340 : 409-13.
6. SCHEEN A. J., DESAIVE C., LEFÈBVRE P. J. Therapy for obesity - today and tomorrow. Baillière's Clin Endocrinol Metab, 1994, 8 : 705-27.
7. CHAGNON Y. C., PÉRUSSE L., BOUCHARD C. The human obesity gene map : the 1997 update. Obes Res, 1998, 6 : 76-92.
8. KIBERSTIS P. A., MARX J. (Eds). Regulation of body weight. Science, 1998, 280: 1363-90.
9. SCHEEN A. J. Lessons from the discovery of leptin : is obesity an endocrine disease? Acta Clin Belg, 1996, 51 : 371-6.
10. FRIEDMAN J. M. Leptin, leptin receptors, and the control of body weight. Nutr Rev, 1998, 56 : S38-S46.
11. REAVEN G. M. Role of insulin resistance in human disease. Diabetes, 1988, 37 : 1595-607.
12. DEFRONZO R. A., FERRANNINI E. Insulin resistance : a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14 : 173-94.
13. MAGGIO C. A., PI-SUNYER F. X. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care, 1997, 20 : 1744-66.
14. HAFFNER S. M., MIETTINEN H. Insulin resistance implications for type II diabetes and coronary heart disease. Am J Med, 1997, 103 : 152-62.
15. BROWN S. A., UPCHURCH S., ANDING R., WINTER M., RAMIREZ G. Promoting weight loss in type II diabetes. Diabetes Care, 1996, 19 : 613-24.
16. SCHEEN A. J. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab, 1998, 23 : 116-23.
17. SCHEEN A. J., LEFÈBVRE A. J. The management of the obese diabetic patient. Diabetes Rev, 1998 ; in press.
18. DESPRÉS J. P. Dyslipidaemia and obesity. Baillière's Clin Endocrinol Metab, 1994, 8 : 629-60.
19. VAN GAAL L. F., ZHANG A., STEIJAERT M. M., DE LEEUW I. H. Human obesity : from lipid abnormalities to lipid oxidation. Int J Obesity, 1995, 19 (Suppl. 3) : S21-6.
20. COUILLARD C., BERGERON N., PRUD'HOMME D. et al. Post-prandial triglyceride response in visceral obesity in men. Diabetes, 1998, 47 : 953-60.
21. MULS E., VANSANT G. Determinants of postprandial lipaemia in obesity. Int J Obesity, 1998, 22 (Suppl.) : in press.
22. DATILLO A., KRIS-ETHERTON P. Effects of weight reduction on blood lipids and lipoproteins : a meta-analysis. Am J Clin Nutr, 1992, 56: 320-8.
23. HUANG Z., WILLETT W. C., MANSON J. A. E. et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med, 1998, 128 : 81-8.
24. REAVEN G. M., LITHELL H., LANDSBERG L. Hypertension and associated metabolic abnormalities : the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 1996, 334 : 374-81.
25. KOLANOWSKI J., DONKIER J. Obesity and hypertension : from pathophysiology to treatment. Int J Obesity, 1998, 22 (Suppl.) : in press.
26. BONORA E., TARGHER G., ZENERE M. B. et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obesity, 1996, 20 : 975-80.
27. LE DEVEHAT C., KHODABANDEHLOU T., DOUGNY M. Etudes des paramètres hémorhéologiques dans l'obésité isolée. Diab Metab, 1992, 18 : 43-7.
28. LUYCKX F. H., SCHEEN A. J., DESAIVE C., DEWÉ W., GIELEN J. E., LEFÈBVRE P. J. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diab Metab, 1998, 24 : 355-61.
29. VALENSI P., PARIES J., MAHEO P. Erythrocyte rheological changes in obese patients : influence of hyperinsulinism. Int J Obesity, 1996, 20 : 814-9.
30. LUYCKX F. H., DESAIVE C., THIRY A. et al. Liver abnormalities in severely obese subjects : effect of drastic weight loss after gastroplasty. Int J Obesity, 1998, 22 : 222-6.
31. LETIEXHE M. R., SCHEEN A. J., GÉRARD P. L., DESAIVE C., LEFÈBVRE P. J. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 80 : 393-9.
32. SCHEEN A., HENRIVAUX P., SCHEEN-LAVIGNE M., JANDRAIN B., PAQUOT N., LEFÈBVRE P. Les cures de jeûne modifié, protidique ou glucido-protidique, dans le traitement de l'obésité morbide. Med Nutr, 1988, 24: 157-64.
33. STOCK M., MUNRO J. Second European Congress on Obesity, satellite conference : very low calorie diets. Int J Obesity, 1989, 13 (Suppl. 2): 1-199.
34. ATKINSON R. L., PI-SUNYER F. X. Very-low-calorie diets. Proceedings of a Satellite Symposium to the 6th International Congress on Obesity. Am J Clin Nutr, 1992, 56: 174S-305S.
35. SCHEEN A., LUYCKX A. S., SCHEEN-LAVIGNE M., LEFÈBVRE P. J. Hormonal and metabolic adaptation to protein supplemented fasting in obese subjects. Int J Obesity, 1982, 6 : 165-74.
36. BRAY G. A. Pharmacological treatment of obesity. In : BRAY G. A., BOUCHARD C., JAMES W. P. T. (eds). Handbook of obesity. New York-Basel-Hong Kong, M. Dekker, 1998 : 953-75.
37. FINER N. Present and future pharmacological approaches. Br Med Bull, 1997, 53 : 409-32.
38. SCHEEN A. J., LEFÈBVRE P. J. Pharmacological treatment of obesity : present status. Int J Obesity, 1998, 22 (Suppl.) : in press.
39. CONNOLLY H. M., CRARY J. L., MCGOON M. D. et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med, 1997, 337 : 581-8.
40. LEAN M. E. J. Sibutramine - a review of clinical efficacy. Int J Obesity, 1997, 21 (Suppl. 1) : S30-6.
41. SJÖSTRÖM L., RISSANEN A., ANDERSEN T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352 : 167-73.
42. DESAIVE C. A critical review of a personal series of 1000 gastroplasties. Int J Obesity, 1995, 19 (Suppl. 3) : S56-60.